Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Jersey for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Jersey only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Jersey (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Elizabeth Fleming (NPI 1154406494)

Field	Value
Entity Type	Individual
Organization	Elizabeth Fleming
Address	150 Park Ave
City	Florham Park
State	NJ
ZIP	07932
Taxonomy	Adult Health Nurse Practitioner
NPI Enumerated	October 26, 2006

Payer Source	Total Paid
Medicare	$2.9M
Medicaid	$0

Key Findings

Service-line profile: The provider’s Medicare code mix is concentrated in high-cost oncology and infusion drugs and related chemotherapy administration procedures, led by J9144 and J9271 alongside multiple chemotherapy administration/add-on codes such as 96413, G0498, 96375, and 96365. This pattern of billed drugs and infusion procedure codes is consistent with an outpatient oncology/infusion practice that delivers biologics, immunotherapies, and supportive treatments on-site rather than a primarily office-based primary care practice.

Revenue concentration: Revenue is highly concentrated in a few drugs — the precomputed top three codes account for 68.9% of Medicare revenue, specifically J9144 ($937.1K, 32.7%), J9271 ($808.4K, 28.2%), and J0897 ($229.5K, 8.0%). These three biologic/oncology-related codes dominate the provider’s $2.9M Medicare revenue base, demonstrating limited revenue diversification within Medicare billing.

Payer mix: This provider is effectively single-payer in scope for billed public programs, reporting $2.9M in total Medicare revenue and no Medicaid billing on file. The absence of Medicaid activity suggests the provider’s Medicaid exposure is negligible and strategic or operational decisions will be driven almost entirely by Medicare reimbursement dynamics.

Competitive standing by code: For J9144 the provider ranks #30 of 615 nationally (95th percentile; notably above typical national volume), indicating a nationally high volume position for daratumumab administration. By contrast, J9271 ranks #461 of 1841 (74th percentile; typical, unremarkable volume) and J0897 ranks #657 of 10057 (93th percentile; typical, unremarkable volume), so the provider is a dominant national participant for some specific infusion drugs but more typical for others.

Statistical outliers and throughput implications: Several administration and supportive codes are called out as extreme outliers or notably above typical national volume — examples include 96413 (rank #104 of 7514, 99th percentile; extreme outlier), 96375 (rank #75 of 5191, 99th percentile; extreme outlier), J0640 (rank #16 of 822, 98th percentile; extreme outlier), and 96372 (99th percentile; extreme outlier). Those labels, together with high claim counts on infusion-related codes, suggest high infusion throughput and frequent per-session drug administrations at this practice.

Supportive drug and biosimilar mix: The profile includes substantial supportive care and biosimilar billing — J2506 (pegfilgrastim, $101.1K, 3.5%) ranks #13 of 586 (98th percentile; notably above typical national volume) while Q5111 (pegfilgrastim biosimilar, $68.7K, 2.4%) and J1561 (immune globulin, $149.7K, 5.2%) also appear in the top lines. This mix indicates routine use of granulocyte colony-stimulating agents and immunoglobulin products alongside oncology biologics, consistent with integrated cancer care and supportive-service workflows.

Low reliance on E/M revenue: Office/outpatient evaluation and management codes contribute only a small share of Medicare revenue (99214: 214 claims, $20.1K, 0.7%; 99215: 66 claims, $8.6K, 0.3%), and their national ranks are typical rather than extreme. The modest E/M contribution relative to high-volume drug and infusion billing reinforces that the practice’s economic model depends primarily on drug administration and procedural reimbursement rather than routine clinic visits.

Tenure and operational inference: The provider’s NPI was enumerated on 2006-10-26 (~20 years ago), indicating a long-standing billing relationship with Medicare. Combined with the concentrated, high-volume infusion and chemotherapy billing patterns, this tenure supports interpretation of an established specialty infusion/oncology operation with sustained Medicare-facing activity.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

56 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	24,660	$40	$937.1K
J9271	Injection, pembrolizumab, 1 mg	18,800	$40	$808.4K
J0897	Injection, denosumab, 1 mg	13,500	$20	$229.5K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	3,940	$40	$149.7K
J1439	Injection, ferric carboxymaltose, 1 mg	104,250	$1	$104.3K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	51,330	$1	$102.7K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	2,900	$40	$101.5K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	1,250	$80	$101.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	930	$100	$93.1K
Q5111	Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg	650	$110	$68.7K

Showing 1–10 of 56

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 56 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Jersey Distribution

Elizabeth Fleming — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Jersey

Full comparison — all codes billed, vs. state median

56 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	11	50	10,650	$40	$580.7K
J9144	2	10	9,090	$40	$480.3K
Q5115	1	10	2,900	$40	$102.7K
J1561	1	10	2,680	$40	$100.3K
J0897	18	380	3,060	$20	$87.8K
Q5111	18	50	580	$110	$76.6K
80053	455	560	90	$10	$50.8K
J2506	2	20	400	$80	$44.4K
J1439	4	70	34,880	$1	$36.5K
J0881	2	30	7,180	$1	$30.6K

Showing 1–10 of 56

Related Providers

Other providers that share a Tax Identification Number (TIN) with Elizabeth Fleming, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
City Medical Of Upper East Side, PLLC	NY	Urgent Care Clinic/Center	$0	$641.6M
Summit Medical Group, Inc	KY	Family Medicine Physician	$0	$95.1M
Glen Gejerman	NJ	Radiation Oncology Physician	$6.5M	$0
Bader Pedemonte	NJ	Hematology (Pathology) Physician	$4.2M	$1.5K
John Sylvester	FL	Radiation Oncology Physician	$2.5M	$0
Elan Diamond	NJ	Hematology & Oncology Physician	$1.9M	$0
William Ding	NJ	Radiation Oncology Physician	$1.7M	$0
John Mccormick	NJ	Diagnostic Radiology Physician	$1.5M	$0
Michael Wax	NJ	Hematology & Oncology Physician	$1.5M	$0
Carol Kornmehl	NJ	Radiation Oncology Physician	$1.4M	$0

Nearby Providers

Other providers in the same ZIP code as Elizabeth Fleming, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
New Jersey Medical Services Group, LLC	NJ	Surgery Physician	$0	$26.3M
Lifeline Medical Associates, LLC	NJ	Obstetrics & Gynecology Physician	$0	$8.8M
Florham Park Endoscopy Asc LLC	NJ	Ambulatory Surgical Clinic/Center	$1.1M	$2M
David Kiken	NJ	Procedural Dermatology Physician	$2.1M	$0
Summit Atlantic Surgery Center LLC	NJ	Ambulatory Surgical Clinic/Center	$1.4M	$0
Mir Ahmad	NJ	Specialist	$1.3M	$0
Andrew Wong	NJ	Radiation Oncology Physician	$699.7K	$0
Anand Patel	NJ	Orthopaedic Surgery Physician	$442.7K	$0
Scott Maron	NJ	Internal Medicine Physician	$421K	$0
Eric Black	NJ	Orthopaedic Surgery Physician	$372.3K	$0

Elizabeth Fleming — Billing Profile & Reimbursement Data

Sign up for Elizabeth Fleming — Billing Profile & Reimbursement Data policy alerts

Elizabeth Fleming — Billing Profile & Reimbursement Data

Sign up for Elizabeth Fleming — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References